Sign in
CompletedPhase 2

Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl

Key facts

Who runs it
Johns Hopkins University
Where
Baltimore, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
76 people enrolled
Started
30 Mar 2022
Ended
3 Aug 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Suvorexant
  • Placebo
Record updated
10 August 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Aged 18-65
  • Meets DSM-5 criteria for opioid use disorder (OUD) with evidence of physical dependence on opioids
  • Provides a urine sample that tests positive for fentanyl and/or fentanyl analogues
  • Interest in being maintained on buprenorphine for OUD
  • Plans to reside in current area for study period
  • Achieving a study maintenance dose of \>=8mg sublingual buprenorphine/naloxone
  • Willing to comply with study protocol
  • Have no clinically significant chronic medical or surgical disorders or conditions that are judged by the investigators to prevent participation

Who cannot take part

  • Medically contraindicated for buprenorphine, extended-release (XR)-buprenorphine (Sublocade), or suvorexant (as per medication labels)
  • Current benzodiazepine or other prescribed medication for the indication of insomnia
  • Severe Diagnostic and Statistical Manual (DSM)-5 alcohol or benzodiazepine use disorder or evidence of alcohol/benzodiazepine physical dependence
  • Have a known allergy to the study medications
  • Current narcolepsy, restless leg syndrome or sleep paralysis
  • Past year clinically-significant psychiatric condition judged to interfere with study participation
  • Severe hepatic or renal impairment; aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>3x upper limit of normal (ULN); Total bilirubin \>2x ULN; Creatinine \>1.5x ULN
  • Pregnant or breast feeding
  • Past 30-day prescribed use of suvorexant for the indication of insomnia
  • Urine sample testing positive for benzodiazepine at screening and admission to residential treatment
  • High risk for current sleep apnea
  • Current (past 30-day) suicidal behaviors
  • Lack of access to stable housing (necessary for electronic pill dispenser charging)
  • Have circumstances that would interfere with study participation (e.g., impending jail)

Where in United States

  • Johns Hopkins Bayview Medical CenterBaltimore, United States

About the trial

What the trial wants to find out

This is a 4-week, randomized-controlled trial of suvorexant vs placebo in persons with opioid use disorder who have recent fentanyl exposure. Participants will first undergo a 5-day residential phase wherein participants are stabilized on sublingual buprenorphine/naloxone, followed by a 3-week outpatient phase wherein participants are maintained on sublingual buprenorphine/naloxone and transitioned to extended-release buprenorphine).

The 2 groups in the trial

  • SuvorexantTreatment being tested

    Nightly dosing of suvorexant

  • PlaceboPlacebo, for comparison

    Nightly dosing of placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Suvorexant as an Adjunct to Buprenorphine Induction and Maintenance in Persons Who Use Fentanyl
Record updated
10 August 2026